Incyte Corporation vs WEC Energy Group Inc. Common Stock — how do they compare? Incyte Corporation trades at $112 (market cap $22.01B), while WEC Energy Group Inc. Common Stock trades at $107.27 (market cap $34.50B). The key difference: WEC Energy Group Inc. Common Stock is the larger of the two by market cap, and WEC Energy Group Inc. Common Stock pays a 3.6% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and WEC Energy Group Inc. Common Stock for 0 Days on average.
| INCY | WEC | |
|---|---|---|
Market Cap | $22.01B | $34.50B |
Volume | 2,589,484 | 2,835,735 |
Sector | Health | Utilities |
52-Week High | $129.93 | $118.85 |
52-Week Low | $86.17 | $100.78 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $17.52B | $57.46B |
Dividend Yield | — | 3.6% |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $111.57, up 0.19% on the day, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q1 and Q2 2026, with EPS of $1.81 and $3.09 respectively, highlight robust profitability. The company's net income margin improved to 27.71% in 2025, and revenue growth is projected to reach $5.8 billion in 2026. Key developments include FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting long-term growth beyond JAKAFI exclusivity post-2029.
The outlook for INCY is positive, driven by pipeline advancements and a $4 billion sales target for non-JAKAFI products. However, risks include reliance on JAKAFI until 2029 and competitive pressures. Analysts maintain a buy consensus with a $132.43 price target, suggesting ~19% upside. Investors should weigh strong cash flow and valuation metrics against execution risks in pipeline commercialization.
WEC Energy Group trades at $105.87, up 0.92% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $0.91 vs. $0.804 expected) and improving profitability (net margin 16.7%). Recent news highlights growing data center demand as a key growth driver, with the company engaging in large-scale customer discussions for 400-500 megawatt projects.
WEC presents a compelling utility investment with stable cash flows and dividend potential, though faces interest rate sensitivity. Analyst consensus targets $118.33 (12% upside) with majority Hold ratings. Key risks include regulatory pressures and capital expenditure requirements for infrastructure expansion through 2030.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →WEC Energy Group is a Midwest electric and natural gas utility holding company whose subsidiaries, including We Energies and Wisconsin Public Service, deliver electricity and natural gas to customers in Wisconsin, Illinois, Michigan, and Minnesota.
Read more on WEC →